*To the editor:*

We read with great interest the article by Dr. Zheng Z and colleagues in the *Journal of Infection* titled "Risk factors of critical & mortal COVID-19 cases: A systematic literature review and meta-analysis",[@bib0001] published online in April 2020. The authors analyzed the risk factors associated with critical illness or death in all COVID-19 patients to help assessing patient status and identify critical patients early. They found male, age \>65, smoking patients were at higher risk of developing into the critical or mortal condition. Some comorbidities, clinical manifestation and laboratory examination might suggest the progression of COVID-19. In this study, we compared the clinical course of severe and critically ill patients with COVID-19, which is of paramount importance to identify indicators for progression from severe to critical illness and thus reduce mortality .

From January 01 to March 17, 2020, we included 31 severe and 20 critically ill patients with COVID-19 from three designated hospitals. All the patients were positive for COVID-19 via real-time fluorescence polymerase chain reaction tests. The patients were diagnosed as severe or critical ill cases according to the trial version 7 of guidelines in China.[@bib0002] We collected epidemiological, clinical, laboratory findings, and treatment from medical records. Two-sample *t*-test, Mann-Whitney U test, *χ*² test, or Fisher\'s exact test were used to compare differences between severe and critically ill cases where appropriate.

Among the 51 patients, 44 (86%) reported COVID-19 exposure history. The mean age of the patients was 59.5 ± 13.6 years (range, 29--89 years) ([Table 1](#tbl0001){ref-type="table"} ). Most patients (67%) were male. 51% patients had chronic diseases, with hypertension (33%) being the most common one, followed by diabetes (14%) ([Table 1](#tbl0001){ref-type="table"}). At onset, fever and dry cough were the most frequent symptoms ([Table 1](#tbl0001){ref-type="table"}). Two severe patients' infection were asymptomatic ([Table 1](#tbl0001){ref-type="table"}). Critically ill cases were concomitant with more chronic illnesses than severe cases (70% vs 39%, *p* = 0.029) ([Table 1](#tbl0001){ref-type="table"}).Table 1Demographics and clinical characteristics of patients with COVID-19.Table 1CharacteristicsAll patients(*n* = 51)Severe patients\
(*n* = 31)Critically ill patients(*n* = 20)P value**Age, years**59.5 ± 13.657.6 ± 13.762.5 ± 13.30.210**Age range, years** 20--291 (2)01 (5)0.392 30--395 (10)5 (16)00.143 40--495 (10)4 (13)1 (5)0.636 50--5910 (20)6 (19)4 (20)1.000 60--6918 (35)10 (32)8 (40)0.572 70--798 (15)3 (10)5 (25)0.237 80--894 (8)3 (10)1 (5)1.000**Sex**0.680 Female17 (33)11 (35)6 (30) Male34 (67)20 (65)14 (70)**Chronic diseases**26 (51)12 (39)14 (70)0.029 Hypertension17 (33)7 (23)10 (50)0.043 Diabetes7 (14)3 (10)4 (20)0.410 Chronic pulmonary disease2 (4)02 (10)0.149 Chronic kidney disease3 (6)1 (3)2 (10)0.553 Cancer4 (8)1 (3)3 (15)0.287 Chronic cardiac disease3 (6)3 (10)00.271 Cerebrovascular disease1 (2)1 (3)01.000 Others4 (8)4 (13)00.145**Symptoms** Fever42 (82)23 (74)19 (95)0.072 Dry cough31 (61)17 (55)14 (70)0.279 Fatigue7 (14)5 (16)2 (10)0.690 Diarrhoea3 (6)2 (6)1 (5)1.000 Headache2 (4)2 (6)00.514 Rhinorrhoea1 (2)01 (5)0.392 Myalgia1 (2)1 (3)01.000 Asymptomatic infection2 (4)2 (6)00.514**Complications** ARDS13 (25)4 (13)9 (45)0.010 Septic shock2 (4)02 (10)0.158 Myocardial injury4 (8)04 (20)0.019 Arrhythmia2 (4)1 (3)1 (5)1.000 Acute kidney injury3 (6)1 (3)2 (10)0.553 Acute liver injury3 (6)2 (6)1 (5)1.000 Hyperglycaemia12 (24)4 (13)8 (40)0.042 Gastrointestinal hemorrhage1 (2)01 (5)0.392 Bacterial co-infection11 (22)4 (13)7 (35)0.085 Fungal co-infection6 (12)3 (10)3 (15)0.668**Treatment** Antiviral drugs49 (96)30 (97)19 (95)1.000 Antibiotic drugs51 (100)31 (100)20 (100)1.000 Antifungal drugs8 (16)3 (10)5 (25)0.237 Corticosteroids39 (76)21 (68)18 (90)0.095 Immunoglobulin39 (76)24 (77)15 (75)1.000 Albumin31 (61)17 (55)14 (70)0.279 Convalescent plasma therapy2 (4)02 (10)0.158 Traditional Chinese medicine36 (71)20 (65)16 (80)0.236 Invasive mechanical ventilation9 (18)09 (45)\<0.001 Non-invasive mechanical ventilation36 (71)21 (68)15 (75)0.579 High-flow nasal cannula oxygen30 (59)15 (48)15 (75)0.059 ECMO1 (2)01 (5)0.392 CRRT3 (6)03 (15)0.055**ICU admission**28 (55)10 (32)18 (90)\<0.001**Clinical outcome** Discharge43 (71)30 (97)13 (65)0.028 Death8 (16)1 (3)7 (35)0.004[^1]

Laboratory findings at admission showed partial pressure of carbon dioxide (*p* = 0.020), lymphocyte count (*p* = 0.007) and albumin (*p* = 0.033) in critically ill cases were significantly lower than that in severe cases ([Table 2](#tbl0002){ref-type="table"} ). However, neutrophil count (*p* = 0.009), aspartate aminotransferase (AST) (*p* = 0.016), fasting blood glucose (FBG) (*p* = 0.001) in critically ill cases were remarkably higher than that in severe cases ([Table 2](#tbl0002){ref-type="table"}).Table 2Laboratory findings of patients with COVID-19.Table 2CharacteristicsAll patients(*n* = 51)Severe patients\
(*n* = 31)Critically ill patients(*n* = 20)*P* valuePartial pressure of oxygen, mmHg76.1 (61.5--89.5)78.5 (69.6--89.6)63.5 (54.5--76.1)0.126Oxygen saturation,%95.9 (90.8--98.4)96.1 (94.5--98.8)94 (88--97.7)0.084Partial pressure of carbon dioxide, mmHg35.7 (32--39.8)38 (34.9--40)32.5 (30.7--39.3)0.020White blood cell count, × 10⁹ per L5.40 (3.77--8.09)5.00 (3.42--6.47)6.57 (4.10--8.96)0.195Neutrophil count, × 10⁹ per L3.30 (2.22--5.59)2.83 (2.12--4.58)5.46 (3.08--7.73)0.009Lymphocyte count, × 10⁹ per L0.86 (0.57--1.21)1.03 (0.71--1.63)0.65 (0.52--0.91)0.007Lactate dehydrogenase, U/L164 (132--213)164 (132--209)161 (131--276)0.602Hemoglobin, g/dL144 (120--166)148 (123--171)129 (113--161)0.243Platelet count, × 10⁹ per L132 (65--198)121 (46--172)146 (80--219)0.255Albumin, g/L36.2 (34.8--39.1)36.9 (35.9--39.3)34.9 (30.8--38.2)0.033AST, U/L32.6 (23.9--44.5)29.7 (21--38.7)37.0 (30.7--58.8)0.016ALT, U/L25.5 (14--43.3)23.3 (14.2--36.9)35.7 (13.3--49.7)0.372APTT, s31.3 (29.3--35.6)31.1 (29.2--35.5)32.1 (29.4--41.7)0.539Prothrombin time, s12.4 (11.9--13.2)12.7 (11.9--13.2)12.4 (11.9--13.3)0.789Creatine, μmol/L84 (65--379)80 (63--309)202.7 (67.1--509)0.300Creatine kinase, U/L81 (50.8--185.5)70 (52.5--156)88 (45--231)0.446Creatine Kinase Isoenzyme MB, U/L12.1 (7.6--14.9)13.2 (7.6--15.5)11.8 (7.4--14.6)0.505High-sensitivity C-reactive protein \>5 mg/L20 (39)11 (35)9 (45)0.497Lactic acid, mmol/L2.6 (1.4--3.85)2.4 (1.48--3.89)3.06 (1.25--3.8)0.744Fasting blood glucose, mmol/L7.16 (5.9--8.68)6.15 (5.39--7.35)8.72 (7.53--10.21)0.001[^2]

As compared with severe patients, critically ill patients were more likely to develop comorbidities, including acute respiratory distress syndrome (ARDS) (45% vs 13%, *p* = 0.010), hyperglycaemia (40% vs 13%, *p* = 0.042), and myocardial injury (20% vs 0%, *p* = 0.019) ([Table 1](#tbl0001){ref-type="table"}). However, there were no significant differences in septic shock (*p* = 0.158), arrhythmia (*p* = 1.000), acute kidney injury (*p* = 0.553), acute liver injury (*p* = 1.000), gastrointestinal hemorrhage (*p* = 0.392), bacterial co-infection (*p* = 0.085), and fungal co-infection (*p* = 0.668) ([Table 1](#tbl0001){ref-type="table"}). Critically ill patients required more intensive care unit (ICU) care (*p* \<0.001) and invasive mechanical ventilation (*p* \<0.001) than severe patients ([Table 1](#tbl0001){ref-type="table"}). Specifically, two (10%) critically ill patients were transfused with convalescent plasma (CP), one (5%) was given extracorporeal membrane oxygenation (ECMO), and three (15%) were treated with continuous renal replacement therapy (CRRT) ([Table 1](#tbl0001){ref-type="table"}). Critically ill patients had significantly higher mortality than severe patients (35% vs 3%, *p* = 0.004) ([Table 1](#tbl0001){ref-type="table"}).

Based on previous studies, evidence suggests that older, male patients are the most susceptible to COVID-19. 48% of COVID-19 patients had comorbid conditions, commonly cardiovascular diseases and diabetes. This rate was significantly higher for critically ill patients, in this study, 70% critically ill cases had more than one chronic disease, such as hypertension and diabetes. Elderly people with underlying diseases are at increased risk of becoming critically ill or dying if they have COVID-19.

Laboratory tests might provide some key clues to indicate critical illness of COVID-19. Lymphocytopenia was a prominent feature of patients with COVID-19 because targeted invasion by viral particles damages the cytoplasmic component of the lymphocyte and causes its destruction.[@bib0003] Lymphocytopenia may reflect the severity of COVID-19 \[3\]. The elevation of AST level was more frequent and significant than the increase of ALT in severe and critically ill patients on hospital admission. Admission AST might be a good indicator of disease severity because AST elevation was positively correlated with the increase of neutrophil counts and the decrease of lymphocyte counts at baseline.[@bib0004] Critically ill patients had significantly higher FBG level, which may attribute to pre-existing diabetes and stress-related hyperglycemia. Diabetes is characterized by chronic hyperglycemia affecting the immune response to the coronavirus. Patients having diabetes were more likely to develop ARDS and require ICU and mechanical ventilation as compared with non-diabetic patients, indicating patients with diabetes had higher risk of progressing to critically ill cases. However, the impact of pre-existing diabetes may be smaller than stress-related hyperglycemia because only 14% patients reported a known history of diabetes. Stress hyperglycemia is a well-described body\'s response and maladaptive mechanism, which may lead to an abnormal inflammatory and immune response contributing to the progression of the COVID-19.[@bib0005] A well-controlled hyperglycemia during COVID-19 may result in a decrease of inflammatory cytokines release and an improvement of prognosis.[@bib0006]

A recent large study showed that 5% of the cases were critically illness characterized by respiratory failure, septic shock, and/or multiple organ dysfunction or failure.[@bib0007] To date, no therapeutics have yet been proven effective for the treatment of critically illness except for supportive care, including treatment with antiviral drugs, antibiotic drugs, corticosteroids, immunoglobulins, and mechanical ventilation. The principal feature of patients with critical illness is the development of ARDS. ECMO is recommended by WHO interim guidelines to support eligible patients with ARDS, while the use of which is restricted to specialised centres globally and technology challenges.[@bib0008] CP had been used as a last resort to improve survival rate of critically ill patients with COVID-19.[@bib0009] It can significant reduce the ICU stay and risk of mortality of patients, which might because that antibodies from convalescent plasma might suppress viraemia.

This study suggested that critically ill patients with COVID-19 had high proportion of underlying diseases and high risk for developing multiple organ failure, which made the treatment more challenging. A well-controlled hyperglycemia is crucial for critically ill patients. Intensive supporting and careful monitoring are necessary to reduce mortality in critically ill patients before effective drugs and vaccines to be developed against COVID-19.
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[^1]: *Note:* Data are n (%) or mean ± standard deviation. p values were calculated by t-test, χ² test or Fisher\'s exact test, as appropriate. Abbreviations: ARDS, acute respiratory distress syndrome; ECMO, extracorporeal membrane oxygenation; CRRT, continuous renal replacement therapy; ICU, intensive care unit.

[^2]: *Note:* Data are median (interquartile range) or n (%). *p* values were calculated by Mann-Whitney U test, χ² test, or Fisher\'s exact test, as appropriate. Abbreviations: AST, aspartate aminotransferase; ALT, alanine aminotransferase; APTT, activated partial thromboplastin time.
